Hikal Ltd., a preferred long-term partner for leading global life sciences companies, Q3 FY25 consolidated revenue recorded at Rs 448 crore.

The working capital and operating cash flow continues to improve and its Pharmaceutical business is capitalizing on China+1 strategy. The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile.

Pharmaceuticals Performance: Revenue stood at Rs. 293 crore and EBIT stood at Rs. 33 crore. API business is experiencing volume growth due to successful global customer acquisition and improved geographical penetration. CDMO business continues to see an increasing flow of new enquiries and several projects are moving up the value chain.

Crop-protection Performance: Revenue stood at Rs. 154 crore and EBIT stood at Rs. 14 crore. The Crop Protection industry has started to exhibit signs of stabilization. The excess inventory situation is gradually resolving as buying at farmer and dealer level is improving. CDMO business has a robust pipeline of 8 projects from both existing and potential clients.

Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said, “In the global pharmaceutical industry, we are witnessing positive momentum led by CDMO opportunities while the crop protection industry is showing signs of stabilization. In Q3 FY25, our revenue amounted to Rs. 448 Cr, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped us to improve our margin profile. Our focused business initiatives have resulted in increased operating cash flows of Rs. 102 Cr YoY on a 9 months basis. Our Board of Directors has recommended an interim dividend of Rs. 0.60 per share (30%)."

"In Q3 FY25, our pharmaceutical revenue stood at Rs. 293 Cr with an EBIT margin of 11.4%, an increase of 449 bps, on a YoY basis. Our CDMO business continues to see an increasing flow of new enquiries as a result of the China+1 strategy by global pharmaceutical companies. We are confident to deliver profitable growth based on a healthy pipeline of projects in various phases of the life cycle. Our API segment continues to gain traction driven by improved geographical penetration and an increased customer base," said Hiremath.

"In Q3 FY25, our crop protection revenue stood at Rs. 154 Cr, with an EBIT margin of 9%. The sector has started to exhibit signs of stabilization, predominantly driven by domestic markets. We are seeing a marginal recovery in volumes, although global market prices for active continue to remain low. In our animal health segment, the project under our long-term agreement with an innovator customer is progressing well and we will conclude the validation over the next two quarters. Our products are undergoing registration and ultimately launching these products in global markets. Under our strategic transformation initiative - Pinnacle, we continue to make substantial strides toward achieving sustainable growth across our businesses. We are witnessing early ]signs of success in development of new capabilities and differentiated technology platforms as well as customers base expansion. We have successfully integrated sustainable practices into our ESG initiatives,” added Hiremath.